Lindsay D. Mitchell

Airdrie, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Journal: British journal of haematology

Published: November 12, 2024

Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.

Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.

Journal: American journal of hematology

Published: December 04, 2023

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: July 07, 2023

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Journal: Annals of hematology

Published: March 23, 2023

One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.

One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.

Journal: European journal of haematology

Published: August 27, 2020

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.

Journal: British journal of haematology

Published: August 14, 2020

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.

Journal: Therapeutic advances in hematology

Published: May 29, 2020

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Journal: PloS one

Published: November 27, 2019

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry.

Journal: British journal of haematology

Published: September 09, 2019

Lessons learned from a review of paroxysmal nocturnal haemoglobinuria (PNH) requests: a report from the UK PNH Network.

Lessons learned from a review of paroxysmal nocturnal haemoglobinuria (PNH) requests: a report from the UK PNH Network.

Journal: British journal of haematology

Published: September 01, 2017

Screening haematology patients for carbapenem-resistant Klebsiella pneumoniae.

Screening haematology patients for carbapenem-resistant Klebsiella pneumoniae.

Journal: Journal of infection prevention

Published: August 16, 2013

Treated follicular lymphoma, recurrent invasive pneumococcal disease, nonresponsiveness to vaccination, and a unique pneumococcus.

Treated follicular lymphoma, recurrent invasive pneumococcal disease, nonresponsiveness to vaccination, and a unique pneumococcus.

Journal: Case reports in hematology

Published: November 19, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026